The first CFC mouse model expresses low levels of the oncogenic BRAF V600E protein (B-Raf+/LSLV600E mutants), a constitutively BRAF active form linked to cancer, but not reported in CFC patients (Urosevic et al., 2011). This evidence concerns the gene BRAF and cardiofaciocutaneous syndrome.